Compare DraftKings Inc (DKNG) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Cassava Sciences Inc — how do they compare? DraftKings Inc trades at $25.15 (market cap $12.51B), while Cassava Sciences Inc trades at $1.09 (market cap $52.66M). The key difference: DraftKings Inc is far larger — about 237.6× Cassava Sciences Inc's market cap, and DraftKings Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| DKNG | FLNA | |
|---|---|---|
Market Cap | $12.51B | $52.66M |
Sector | Consumer Cyclical | Health |
52-Week High | $48.23 | $4.64 |
52-Week Low | $20.72 | $1.09 |
Enterprise Value | $13.43B | -$33.92M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $26.45, showing minimal daily movement. The stock exhibits a bullish technical trend with strong moving average signals, supported by a positive cash flow turnaround to $274.40 million in 2025. Revenue growth has been robust, rising from $2.2 billion in 2022 to $6.05 billion in 2025, with the company achieving its first net profit of $3.71 million. Recent expansion into Alberta and the launch of prediction markets highlight ongoing growth initiatives.
The outlook is positive, driven by analyst consensus with a $34.18 price target and 73% buy ratings. Key catalysts include upcoming sports events and product launches, but risks involve high valuation multiples and regulatory scrutiny. Profitability remains nascent, requiring sustained execution to justify current premiums.
FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.
Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
